title: Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) retreatment is rarely administered for non-small cell lung cancer (NSCLC) patients who did not respond to previous TKI treatment. A high dose of TKI may overcome resistance to the standard dose of TKI and have different effectiveness toward cancer compared with the standard dose of TKI. This manuscript describes a dramatic and durable response to high-dose icotinib in a NSCLC patient who did not respond to a previous standard dose of erlotinib. The treatment extended the life of the patient for one additional year. A higher dose of icotinib deserves further study not only for patients whose therapy failed with the standard dose of TKI but also for newly diagnosed NSCLC patients with a sensitive mutation. Serial mutation testing during disease development is necessary for analysis and evaluation of EGFR TKI treatment.
authors.affiliation: Department of Medical Oncology, The Chinese PLA General Hospital, Beijing 100853, China. Electronic address: guanyin75@sina.com.
authors.forename: Yin
authors.initials: Y
authors.lastname: Guan
authors.affiliation: Department of Medical Oncology, The Chinese PLA General Hospital, Beijing 100853, China; Department of Medical Oncology, The Chinese PLA General Hospital (Hainan Branch), Sanya 572013, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, The Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Meng
authors.affiliation: Department of Medical Oncology, The Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Yan
authors.affiliation: Department of Medical Oncology, The Chinese PLA General Hospital, Beijing 100853, China. Electronic address: jiaosc@vip.sina.com.
authors.forename: ShunChang
authors.initials: S
authors.lastname: Jiao
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D043844:Crown Ethers / Q000008:administration & dosage* / Q000009:adverse effects; D000077143:Docetaxel; D054796:Drug Dosage Calculations; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009367:Neoplasm Staging; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D016879:Salvage Therapy; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D017211:Treatment Failure
chemical_list: D043844:Crown Ethers; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; C531470:icotinib; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D002945:Cisplatin
keywords: Epidermal growth factor receptor; High dose; Icotinib; Mutation; Non-small cell lung cancer; Tyrosine kinase inhibitor